| 000 | 01819 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517072900.0 | ||
| 264 | 0 | _c20161213 | |
| 008 | 201612s 0 0 eng d | ||
| 022 | _a1473-4877 | ||
| 024 | 7 |
_a10.1185/03007995.2016.1140026 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBetts, Keith A | |
| 245 | 0 | 0 |
_aAn indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis. _h[electronic resource] |
| 260 |
_bCurrent medical research and opinion _c2016 |
||
| 300 |
_a721-9 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; Systematic Review | ||
| 650 | 0 | 4 |
_aAdalimumab _xadministration & dosage |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aArthritis, Psoriatic _xdrug therapy |
| 650 | 0 | 4 | _aBayes Theorem |
| 650 | 0 | 4 |
_aBiological Products _xadministration & dosage |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aComparative Effectiveness Research |
| 650 | 0 | 4 | _aCosts and Cost Analysis |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aModels, Economic |
| 650 | 0 | 4 | _aNetwork Meta-Analysis |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aThalidomide _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGriffith, Jenny | |
| 700 | 1 | _aFriedman, Alan | |
| 700 | 1 | _aZhou, Zheng-Yi | |
| 700 | 1 | _aSignorovitch, James E | |
| 700 | 1 | _aGanguli, Arijit | |
| 773 | 0 |
_tCurrent medical research and opinion _gvol. 32 _gno. 4 _gp. 721-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1185/03007995.2016.1140026 _zAvailable from publisher's website |
| 999 |
_c25610480 _d25610480 |
||